0
0
In July 2025, the Central Drugs Standard Control Organization (CDSCO) of India declared 46 batches of medicines as “Not of Standard Quality” (NSQ) after testing by its regional and central laboratories revealed they did not meet required pharmacopeial standards. These medicines included commonly prescribed antibiotics, cardiac drugs, gastrointestinal medicines, hormonal injections, and pain relief products widely used across the country. The quality failures were identified through rigorous tests assessing parameters such as assay content, dissolution, sterility, uniformity, and presence of impurities .
Key Findings from CDSCO Testing
The flagged batches encompassed drugs including Azithromycin Tablets IP (Aziventis-500), Heparin Injection IP 1000 IU/ml (Flagorin), Amikacin Sulphate Injection, Amoxycillin and Potassium Clavulanate Tablets I.P. 625 mg, and Dexamethasone Tablets IP 4mg (Dexatore-4), among others. Failures included particulate matter contamination, assay discrepancies, inadequate dissolution rates, sterility failures, and presence of foreign fibers. These quality parameters are critical for ensuring drug safety, efficacy, and uniformity batch-to-batch .
Testing was carried out at CDSCO’s central and regional laboratories located in major cities like Kolkata, Mumbai, Chennai, Hyderabad, and Chandigarh. Each lab independently confirmed the non-compliance of multiple batches with the Indian Pharmacopoeia standards, which form the basis for quality expectations under the Drugs and Cosmetics Act, 1940 .
Understanding Not of Standard Quality (NSQ) Drugs
Drugs classified as NSQ are those that fail to meet the minimum quality standards legally mandated. Section 16 (1) (a) of the Drugs and Cosmetics Act defines standards of quality as those matching the specifications in the Act’s Second Schedule. Medications not meeting these standards pose a risk to patient safety due to potential inefficacy or harmful contaminants .
Expert Commentary
Dr. Rakesh Sharma, a clinical pharmacologist not involved with CDSCO’s testing, explained, “Quality lapses like sterility failure or presence of particulate matter can lead to serious health risks including infections or reduced therapeutic benefit. Continuous vigilance and strict regulatory enforcement are essential to protect public health.” He emphasized the importance of batch-level quality checks to avoid harmful drugs reaching consumers .
Public Health Implications
These findings highlight the ongoing challenges in ensuring pharmaceutical quality in India’s vast drug manufacturing sector. The presence of substandard medicines can contribute to treatment failures, antimicrobial resistance, and adverse reactions, undermining healthcare outcomes. The CDSCO’s alert serves as a critical reminder of the need for robust quality control systems throughout the drug supply chain .
For patients and healthcare providers, this means extra caution in sourcing medicines from reputable manufacturers and pharmacies. Clinicians should monitor patient responses and report any suspected drug inefficacy or adverse reactions promptly to regulatory bodies. Public awareness about the risks of poor-quality medicines can empower consumers to demand safe, effective products .
Limitations and Counterpoints
While the alert identifies batches as NSQ, it does not implicate entire product lines or manufacturers universally. Some failures were specific to individual batches, underscoring the need for continuous, batch-wise testing rather than generalizing quality issues. Additionally, regulatory agencies often undertake corrective actions such as recalling affected batches and imposing penalties, mitigating widespread impact .
The CDSCO’s testing transparency and public dissemination of NSQ alerts align with global best practices, fostering accountability. However, critics argue that enhanced resources, technology upgrades, and strengthened post-market surveillance are needed to mitigate recurring quality lapses .
Practical Takeaways for Readers
-
Purchase medicines from licensed pharmacies sourcing from trusted manufacturers.
-
Consult healthcare professionals if a prescribed drug seems ineffective or causes unexpected side effects.
-
Report suspected substandard or counterfeit medicines to health authorities.
-
Advocate for systemic improvements in pharmaceutical regulation and quality assurance.
In summary, the CDSCO’s July 2025 quality alerts underscore ongoing vigilance needs in India’s drug quality landscape, with implications for patient safety and public health that require proactive stakeholder engagement.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References:
-
Central Drugs Standard Control Organization (CDSCO). “46 Drug Batches Fail CDSCO Quality Test In July, Details.” Medical Dialogues, August 2025.
